Compare KROS & NBBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KROS | NBBK |
|---|---|---|
| Founded | 2015 | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 655.9M | 718.5M |
| IPO Year | 2020 | N/A |
| Metric | KROS | NBBK |
|---|---|---|
| Price | $19.22 | $20.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 1 |
| Target Price | $23.00 | $23.00 |
| AVG Volume (30 Days) | ★ 365.3K | 208.6K |
| Earning Date | 02-25-2026 | 01-22-2026 |
| Dividend Yield | N/A | ★ 1.37% |
| EPS Growth | N/A | ★ 420.99 |
| EPS | ★ 1.57 | 1.54 |
| Revenue | ★ $246,718,000.00 | $189,481,000.00 |
| Revenue This Year | $6,924.79 | $43.56 |
| Revenue Next Year | N/A | $23.60 |
| P/E Ratio | ★ $12.19 | $13.24 |
| Revenue Growth | ★ 37798.31 | 30.69 |
| 52 Week Low | $9.12 | $15.09 |
| 52 Week High | $22.55 | $21.58 |
| Indicator | KROS | NBBK |
|---|---|---|
| Relative Strength Index (RSI) | 49.60 | 54.54 |
| Support Level | $18.33 | $19.49 |
| Resistance Level | $19.67 | $20.31 |
| Average True Range (ATR) | 0.70 | 0.49 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 70.37 | 50.83 |
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
NB Bancorp Inc operates as the holding company of Needham Bank. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, and consumer loans.